William Blair analyst Myles Minter downgraded Vigil Neuroscience (VIGL) to Market Perform from Outperform without a price target after the company agreed to be acquired by Sanofi for $ per share upfront.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIGL:
- Vigil Neuroscience downgraded to Market Perform from Outperform at Citizens JMP
- Vigil Neuroscience to be acquired by Sanofi for $8.00 per share
- Vigil Neuroscience Inc trading halted, news pending
- Vigil Neuroscience Advances Clinical Trials and Financial Stability
- Vigil Neuroscience reports Q1 EPS (49c) vs. (50c) last year